Quest Laboratories (NSE:QUESTLAB) EBITDA per Share: ₹1.71 (TTM As of Mar. 2026)


NSE:QUESTLAB Quest Laboratories Ltd NSE:QUESTLAB
44 GF Score
Price ₹98.05
! 8 Warning Signs
View Full Analysis

What is Quest Laboratories EBITDA per Share?

Quest Laboratories NSE:QUESTLAB -1.56% 44 EBITDA per Share is ₹1.71 as of Mar. 2026. GuruFocus rates NSE:QUESTLAB with a GF Score™ of 44/100. The stock has 8 warning signs investors should review. Among 815 Drug Manufacturers companies, Quest Laboratories ranks worse than 96.2% on this metric.

Quest Laboratories's EBITDA per Share for the three months ended in Mar. 2026 was ₹1.71. Its EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1.71.

During the past 12 months, the average EBITDA per Share Growth Rate of Quest Laboratories was 2.70% per year. During the past 3 years, the average EBITDA per Share Growth Rate was -44.60% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 51.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Quest Laboratories's EBITDA per Share or its related term are showing as below:

NSE:QUESTLAB' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -44.6   Med: 46   Max: 120.5
Current: -44.6

During the past 6 years, the highest 3-Year average EBITDA per Share Growth Rate of Quest Laboratories was 120.50% per year. The lowest was -44.60% per year. And the median was 46.00% per year.

NSE:QUESTLAB's 3-Year EBITDA Growth Rate is ranked worse than
96.2% of 815 companies
in the Drug Manufacturers industry
Industry Median: 8.9 vs NSE:QUESTLAB: -44.60

Quest Laboratories's EBITDA for the three months ended in Mar. 2026 was ₹28.3 Mil.

During the past 12 months, the average EBITDA Growth Rate of Quest Laboratories was 2.80% per year. During the past 3 years, the average EBITDA Growth Rate was 37.30% per year. During the past 5 years, the average EBITDA Growth Rate was 64.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 6 years, the highest 3-Year average EBITDA Growth Rate of Quest Laboratories was 120.40% per year. The lowest was 37.30% per year. And the median was 46.00% per year.


Quest Laboratories  (NSE:QUESTLAB) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Quest Laboratories EBITDA per Share Related Terms


Quest Laboratories EBITDA per Share Historical Data

* Premium members only.

The historical data trend for Quest Laboratories's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Quest Laboratories EBITDA per Share Chart

Quest Laboratories Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBITDA per Share
Get a 7-Day Free Trial 3.97 74.49 9.60 12.34 12.68

Quest Laboratories Quarterly Data
Mar21 Mar22 Mar23 Sep23 Dec23 Mar24 Mar25 Mar26
EBITDA per Share Get a 7-Day Free Trial 0.00 1.68 2.17 2.78 1.71
NSE:QUESTLAB
44GF Score
Quest Laboratories Ltd NSE:QUESTLAB
EBITDA per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Quest Laboratories EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Quest Laboratories's EBITDA per Share for the fiscal year that ended in Mar. 2026 is calculated as

EBITDA per Share(A: Mar. 2026 )
=EBITDA/Shares Outstanding (Diluted Average)
=207.848/16.395
=12.68

Quest Laboratories's EBITDA per Share for the quarter that ended in Mar. 2026 is calculated as

EBITDA per Share(Q: Mar. 2026 )
=EBITDA/Shares Outstanding (Diluted Average)
=28.282/16.497
=1.71

EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of ₹1.71 mean?
Quest Laboratories (NSE:QUESTLAB) has a EBITDA per Share of ₹1.71 as of Mar. 2026. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Quest Laboratories and its competitors. According to the industry distribution chart, Quest Laboratories ranks #784 out of 815 companies in the Drug Manufacturers industry, placing it in the top 96.2%.
Is Quest Laboratories' EBITDA per Share too high?
Quest Laboratories' current EBITDA per Share is ₹1.71. Based on the distribution chart, Quest Laboratories ranks #784 out of 815 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Quest Laboratories has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Quest Laboratories' EBITDA per Share compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Quest Laboratories ranks #784 out of 815 companies for EBITDA per Share. This places Quest Laboratories in the lower half of its industry. The industry median EBITDA per Share is 8.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Drug Manufacturers company?
The median EBITDA per Share among Drug Manufacturers companies is 8.90, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Quest Laboratories and its competitors. For the Drug Manufacturers industry, the median EBITDA per Share is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quest Laboratories's current EBITDA per Share is ₹1.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Laboratories stock overvalued right now?
Quest Laboratories (NSE:QUESTLAB) has a current EBITDA per Share of ₹1.71. The current EBITDA per Share is ₹1.71. Quest Laboratories' overall GF Score™ is 44/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For Quest Laboratories (NSE:QUESTLAB), the current EBITDA per Share is ₹1.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Quest Laboratories Business Description

Address Sector III, Plot No. 45, Pithampur Industrial Area, Opposite Kissan Pipe Unit 4, District Dhar, Pithampur, Dhar, MP, IND, 454775
Quest Laboratories Ltd is engaged in the business of manufacturing pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. It produces various products, comprising ethical drugs, generic drugs, and over-the-counter drugs, and is also available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids, among others. The company operates in a single segment of Drugs and Chemicals.
44GF Score

Get the complete analysis for NSE:QUESTLAB

EBITDA per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹98.05
Price